Blood INR TTR Warfarin adjustment
Conditions
Interventions
The weekly dosage of warfarin for all participants remains unchanged while the prescription method would be adjusted according to the study protocol, depending on the patient group. The patients in gr
Active Comparator Behavioral,Active Comparator Behavioral
The split tablet, same daily-dosing regimen (Group S),The whole tablet, alternate-day dosing regimen (Group A)
Sponsors
Siriraj Research Development Fund (Managed by Routine to Research: R2R)
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: The anticoagulated patients who followed up at the outpatient clinic of the Division of Cardio-Thoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand Eligible patients had six months or longer history of stable therapeutic INR levels of 2.0 to 3.0 achieved by the specific weekly dose of warfarin in the dosage protocol (14, 17.5, 21, 24.5, 28, 31.5 mg/week) and could comply with 6 months follow up protocol.
Exclusion criteria
Exclusion criteria: The patients whose a period of warfarin discontinuation was possibly needed were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time in therapeutic range: TTR At 6-week interval for 6 months Rosendaal methods | — |
Secondary
| Measure | Time frame |
|---|---|
| The dosage change incidence, INR levels, the bleeding and thromboembolic events of the warfarin, the compliance and adherence of the participants. At 6-week interval for 6 months Incident | — |
Countries
Thailand
Contacts
Public ContactChanyapat Kaewsaengeak
Siriraj
Outcome results
None listed